Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Chronic Myelocytic Leukemia (CML) Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Myelocytic Leukemia (CML) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chronic Myelocytic Leukemia (CML) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Chronic Myelocytic Leukemia (CML) Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chronic Myelocytic Leukemia (CML) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Chronic Myelocytic Leukemia (CML) Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chronic Myelocytic Leukemia (CML) Therapeutics therapeutics market.
• Analysis of key recent licensing and partnership agreements in Chronic Myelocytic Leukemia (CML) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Chronic Myelocytic Leukemia (CML) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chronic Myelocytic Leukemia (CML) Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Chronic Myelocytic Leukemia (CML) Therapeutics market landscape? – Identify, understand and capitalize.

TABLE OF CONTENTS

1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures

2 CHRONIC MYELOGENOUS LEUKEMIA (CML) THERAPEUTICS: INTRODUCTION
2.1 Overview
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology
2.5 Staging of CML
2.6 Risk factors for CML
2.7 Diagnosis
2.7.1 Lab Tests for the Diagnosis of Patients with CML
2.7.2 Genetic Tests:
2.8 Treatment of CML
2.8.1 Targeted Therapy
2.8.2 Chemotherapy
2.8.3 Surgery
2.8.4 Biologic Therapy
2.8.5 High-Dose Chemotherapy with Stem Cell Transplant
2.8.6 Donor Lymphocyte Infusion
2.8.7 Treatment of CML Patients by Different Phases
2.8.8 Treatment Options on the Basis of Line of Treatment
2.9 GlobalData Pipeline Report Guidance

3 CHRONIC MYELOGENOUS LEUKEMIA (CML) THERAPEUTICS: MARKET CHARACTERIZATION
3.1 CML Therapeutics Market Size (2005-2010) – Global
3.2 CML Therapeutics Market Forecast (2010-2017) – Global
3.3 CML Therapeutics Market Size (2005-2010) – The US
3.4 CML Therapeutics Market Forecast (2010-2017) – The US
3.5 CML Therapeutics Market Size (2005-2010) – France
3.6 CML Therapeutics Market Forecast (2010-2017) – France
3.7 CML Therapeutics Market Size (2005-2010) – Germany
3.8 CML Therapeutics Market Forecast (2010-2017) – Germany
3.9 CML Therapeutics Market Size (2005-2010) – Italy
3.10 CML Therapeutics Market Forecast (2010-2017) – Italy
3.11 CML Therapeutics Market Size (2005-2010) – Spain
3.12 CML Therapeutics Market Forecast (2010-2017) – Spain
3.13 CML Therapeutics Market Size (2005-2010) – The UK
3.14 CML Therapeutics Market Forecast (2010-2017) – The UK
3.15 CML Therapeutics Market Size (2005-2010) – Japan
3.16 CML Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers for the CML Therapeutics Market
3.17.1 Drivers for the CML Therapeutics Market
3.17.2 Barriers for the CML Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway

4 CHRONIC MYELOGENOUS LEUKEMIA (CML) THERAPEUTICS: COMPETITIVE ASSESSMENT
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Product Profiles for the Major Marketed Products in the CML Therapeutics Market
4.2.1 Gleevec/Glivec (imatinib mesylate)
4.2.2 Sprycel (dasatinib)
4.2.3 Tasigna (nilotinib)
4.3 Key Takeaway

5 CHRONIC MYELOGENOUS LEUKEMIA (CML) THERAPEUTICS: PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 CML Therapeutics – Pipeline by Phases of Development
5.3.1 CML Therapeutics – Phase III Pipeline
5.3.2 CML Therapeutics – Phase II Pipeline
5.3.3 CML Therapeutics – Phase I Pipeline
5.3.4 CML Therapeutics – Pre-clinical Pipeline
5.3.5 CML Therapeutics – Discovery Pipeline
5.3.6 Technology Trends Analytic Framework
5.4 CML Therapeutics – Pipeline by Mechanism of Action
6.5 CML Therapeutics – Promising Drugs under Clinical Development
5.5 Molecule Profile for Promising Drugs Under Clinical Development
5.5.1 Omapro (omacetaxine mepesuccinate)
5.5.2 Bosutinib (SKI-606)

6 CHRONIC MYELOGENOUS LEUKEMIA (CML) THERAPEUTICS: CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Top Companies Participating in CML Therapeutics Clinical Trials

7 CHRONIC MYELOGENOUS LEUKEMIA (CML) THERAPEUTICS: STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 CML Therapeutics: Implications for Future Market Competition

8 CHRONIC MYELOGENOUS LEUKEMIA (CML) THERAPEUTICS: FUTURE PLAYERS
8.1 Introduction
8.2 Company Profiles
8.2.1 Novartis AG
8.2.2 Bristol-Myers Squibb (BMS)
8.2.3 Cephalon, Inc.
8.2.4 Pfizer Inc.
8.2.5 Other Companies in the CML Therapeutics Market

9 CHRONIC MYELOGENOUS LEUKEMIA (CML) THERAPEUTICS: LICENSING AND PARTNERSHIP DEALS

10 CML THERAPEUTICS: APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

LIST OF TABLES

Table 1: CML Diagnosis Percentage by Age Group, 2004-2008
Table 2: CML Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 3: CML Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 4: CML Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 5: CML Therapeutics Market, The US, Forecast ($m), 2010–2017
Table 6: CML Therapeutics Market, France, Revenue ($m), 2005–2010
Table 7: CML Therapeutics Market, France, Forecast ($m), 2010–2017
Table 8: CML Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 9: CML Therapeutics Market, Germany, Forecast ($m), 2010–2017
Table 10: CML Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 11: CML Therapeutics Market, Italy, Forecast ($m), 2010–2017
Table 12: CML Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 13: CML Therapeutics Market, Spain, Forecast ($m), 2010–2017
Table 14: CML Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 15: CML Therapeutics Market, The UK, Forecast ($m), 2010–2017
Table 16: CML Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 17: CML Therapeutics Market, Japan, Forecast ($m), 2010–2017
Table 18: CML Therapeutics – Phase III Pipeline, 2011
Table 19: CML Therapeutics – Phase II Pipeline, 2011
Table 20: CML Therapeutics – Phase I Pipeline, 2011
Table 21: CML Therapeutics – Pre-clinical and Discovery Pipeline, 2011
Table 22: CML Therapeutics – Discovery Pipeline, 2011
Table 23: CML Therapeutics – Promising Drugs Under Clinical Development, 2011
Table 24: CML Therapeutics – Clinical Trials by Country, 2011
Table 25: CML Therapeutics – Clinical Trials by Phase, 2011
Table 26: CML Therapeutics – Clinical Trials by Status, 2011
Table 27: CML Therapeutics – Prominent Sponsors, 2011
Table 28: CML Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 29: Novartis AG Deals, 2009-2011
Table 30: Bristol Myers Squibb, Deals, 2009-2011
Table 31: Cephalon Inc. – Oncology, Pipeline, 2011
Table 32: Cephalon Inc. – CML, Pipeline, 2011
Table 33: Cephalon Inc. Deals, 2011
Table 34: Pfizer Inc. – Oncology, Pipeline, 2011
Table 35: Pfizer Inc. – CML, Pipeline, 2011
Table 36: Pfizer Inc. Deals, 2009-2011
Table 37: CML Therapeutics Market – Future Players
Table 38: CML Therapeutics, Global, Deals, 2009-2011

LIST OF FIGURES

Figure 1: Hematopoisis, Blood Stem Cell Goes Through Several Steps to Become a RBC, WBC and Platelet
Figure 2: Formation of Philadelphia (Ph) chromosome
Figure 3: Staging of CML
Figure 4: Bone Marrow Aspiration and Biopsy
Figure 5: Testing for CML
Figure 6: CML Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 7: CML Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 8: CML Therapeutics Market, the US, Revenue ($m), 2005–2010
Figure 9: CML Therapeutics Market, The US, Forecast ($m), 2010–2017
Figure 10: CML Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 11: CML Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 12: CML Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 13: CML Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 14: CML Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 15: CML Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 16: CML Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 17: CML Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 18: CML Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 19: CML Therapeutics Market, The UK, Forecast ($m), 2010–2017
Figure 20: CML Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 21: CML Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 22: Opportunity and Unmet Need in the CML Therapeutics Market, 2011
Figure 23: CML Therapeutics – Strategic Competitor Assessment, 2011
Figure 24: CML Therapeutics – Pipeline by Phase of Development, 2011
Figure 25: CML Therapeutics – Technology Trends Analytic Framework, 2011
Figure 26: CML Therapeutics – Technology Trends Analytic Framework – Description, 2011
Figure 27: CML Therapeutics – Pipeline by Mechanism of Action, 2011
Figure 28: CML Therapeutics – Clinical Trials by Country, 2011
Figure 29: CML Therapeutics – Clinical Trials by Phase, 2011
Figure 30: CML Therapeutics – Clinical Trials by Status, 2011
Figure 31: CML Therapeutics – Overall Sponsors, 2011
Figure 32: CML Therapeutics – Prominent Sponsors, 2011
Figure 33: CML Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 34: CML Therapeutics Market, Drivers and Restraints 2011
Figure 35: Implications for Future Market Competition in the CML Therapeutics Market, 2011
Figure 36: CML Therapeutics Market – Pipeline by Company, 2011
Figure 37: GlobalData Market Forecasting Model